EBIT (Annual)

EBIT: Income before interest and taxes.

Urogen Pharma (URGN) had EBIT of $-124.86M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$109.79M
Net Income	$-153.49M
Cost of Goods Sold	$12.45M
Gross Profit	$97.34M
Operating Expenses	$234.65M
Operating Income	$-124.86M
Non-Operating Income/Expense	$-28.55M
Pre-Tax Income	$-153.42M
Normalized Pre-Tax Income	$-153.42M
Income after Taxes	$-153.49M
Income from Continuous Operations	$-153.49M
Consolidated Net Income/Loss	$-153.49M
Normalized Income after Taxes	$-153.49M
EBIT	$-124.86M
EBITDA	$-126.43M
Weighted-Average Shares Outstanding (Basic)	48.12M
Weighted-Average Shares Outstanding (Diluted)	48.12M
Earnings per Share (EPS) (Basic)	$-3.19
Earnings per Share (EPS) (Diluted)	$-3.19
Balance Sheet Financials
Current Assets	$186.02M
Property, Plant, and Equipment	$0.64M
Long-Term Assets	$14.43M
Total Assets	$200.46M
Current Liabilities	$46.42M
Long-Term Debt	$122.21M
Long-Term Liabilities	$259.51M
Total Liabilities	$305.93M
Common Equity	$-105.47M
Tangible Shareholders Equity	$-105.47M
Shareholders Equity	$-105.47M
Common Shares Outstanding	48.35M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-162.44M
Cash Flow from Investing Activities	$61.56M
Cash Flow from Financial Activities	$39.92M
Beginning Cash	$173.06M
End Cash	$112.09M
Increase/Decrease in Cash	$-60.97M
Stock-Based Compensation	$11.96M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.01
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	7.30
Debt to Equity Ratio	-1.16
Gross Margin	88.66%
Operating Margin	-113.73%
EBIT Margin	-113.73%
EBITDA Margin	-115.16%
Pre-Tax Profit Margin	-139.74%
Profit Margin	-139.81%
Free Cash Flow	$-162.73M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.55
Inventory Turnover	0.76
Receiveable Turnover	3.32
Days Sales in Receivables	109.98
Return on Equity	145.53%
Return on Tangible Equity	145.53%
Return on Assets	-76.57%
Return on Investments	-917.15%
Book Value Per Share	$-2.18
Free Cash Flow per Share	$-3.38
Operating Cash Flow per Share	$-3.38

Data from Zacks Investment Research, Inc.